Based on the amyloid cascade hypothesis, many reports have indicated that immunotherapy is beneficial for Alzheimer's disease (AD). We developed a mucosal immunotherapy for AD by nasal administration of recombinant Sendai virus vector carrying A␤1-43 and mouse IL-10 cDNA. Nasal but not intramuscular administration of the vaccine induced good antibody responses to A␤. When APP transgenic mice (Tg2576) received this vaccine once nasally, the A␤ plaque burden was significantly decreased 8 weeks after without inducing inflammation in the brain. The amount of A␤ measured by ELISA was also reduced in both soluble and insoluble fractions of the brain homogenates, and notably the A␤ oligomer (12-mer) was also apparently decreased. Tg2576 mice showed significant improvement in cognitive functions examined at 3 months after vaccination. Thus, this is an alternative immunotherapy for AD, which has an advantage in non-invasive, safe and relatively long lasting features.
passive immunization are under investigation. However, repeated injections of monoclonal anti-A␤ antibody are required, which may produce anti-idiotype and neutralizing antibodies. Increases of micro-hemorrhage and vasogenic edema have also been reported after systemic administration of anti-A␤ antibodies into APP-tg mice and humans [14] [15] [16] . Furthermore, passive immunization is not useful for prophylaxis for diseases with insidious onset such as AD. Thus, active immunization, if it is safe and easy, still has an advantage. One of the active immunizations is intramuscular injection of DNA encoding A␤ [17, 18] . However, repeated injections are required, and it may require a strategy of suppressing T helper 1 (Th1) immune responses. The mucosal immune system representing Peyer's patch and nasopharyngeal associated lymphoid tissue (NALT) has distinct functions such as predominant humoral immune responses and efficient immune induction via mucosal tissue. To induce mucosal immune responses nasal administration of A␤ peptide and adjuvant has been successful in mice [19, 20] . However, use of adjuvant induces T cell infiltration in the brain. Administration of viral vectors carrying cDNA encoding genes of targeting antigens can stimulate mucosal immune system without adjuvant [21] . Now, we have developed a new nasal vaccine for AD by using the recombinant Sendai virus (SeV) vector. We found an excellent effect of the vaccine in APP-tg mice (Tg2576) pathologically and functionally without inducing brain inflammation. 
Materials and methods

Ethics
This work was conducted in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki). All experiments were performed in accordance with Guidelines for Animal Experiments of the NCGG/NILS animal experimentation committee and of Nagoya University School of Medicine. The procedures involving animals and their care conformed to the international guidelines set out in "Principles of Laboratory Animal Care" (NIH publication no. 85-23, revised 1985).
Mice
Tg2576 mice [22] expressing the Swedish mutation of APP (APPK670N, M671L) at high levels under control of the hamster prion protein (PrP) promoter were obtained from Taconic Co. (USA). Animals were kept in a specific-pathogen-free condition and fed ad libitum.
Recombinant Sendai virus vector
We developed recombinant SeV vector carrying human A␤1-43 cDNA and mouse interleukin-10 (mIL-10) cDNA (rSeV-A␤). Recombinant SeV vector carrying LacZ cDNA (rSeV-LacZ) was used as control. The experiment was approved by the recombinant DNA experiment safety committee in the institutions.
In order to make the vaccine, we utilized F gene-deleted non-transmissible SeV [23] further bearing temperature-sensitive mutations in M (G69E, T116A, and A183S), HN (A262T, G264R, and K461G) [24] , P (L511F) and L (N1197S, K1795E) identified in SeV strains capable of persistent infection in vitro [25] . Thus generated and named SeV/TS F vector was used to construct the SeV 18+ A␤1-43/TS F-mIL10 vector carrying A␤1-43 gene with APP secretion signal [21] and mIL10 according to the method described previously with a little modification [23, 24, 26] (Fig. 1 ). In brief, A␤1-43 gene was amplified with a pair of NotI-tagged primers that contained SeV-specific transcriptional regulatory signal sequences, 5 -ATTGCGGCCGCCAAGGTTCACTTATGCTGCCCGGTTT-GGCACTGCTCCTG-3 and 5 -ATTGCGGCCGCGATGAACTTTCACCCT-AAGTTTTTCTTACTACGG TTAAGTCGCTATGACAACACCGCCCACCAT-GAGTCC-3 . The amplified fragment was introduced into the NotI site of the parental pSeV 18+ /TS F, cDNA of SeV/TS F, to generate pSeV 18+ A␤43/TS F. mIL-10 (accession no. NP 034678) cDNA that was amplified with a pair of NotI-tagged primers, 5 -ACTTGCGGCCGCCAAAGTTCAATGCCTGGCTCAGCACTGCTATGCTG-CCTG-3 and 5 -ATCCGCGGCCGCGATAACTTTCACCCTAAGTTTTTCT-TACTACG GTTAGCTTTTCATTTTGATCATCATGTATGCTTC-3 , was subcloned into the F gene-deleted site of the LitmusSalINheIhfrag-TS F carrying the SalI and NheI digested fragment containing M and HN genes from pSeV 18+ /TS F in LITMUS38 (NEB) [27] . The SalI and NheI digested fragment of pSeV 18+ A␤1-43/TS F was substituted with the corresponding fragment of the mIL10 gene-introduced LitmusSalINheIhfrag-TS F. The cDNA of SeV 18+ LacZ/TS F (pSeV 18+ lacZ/TS F) was constructed in similar manner using an amplified fragment of LacZ [26] . pSeV 18+ A␤1-43/TS F-mIL10 or pSeV 18+ LacZ/TS F was transfected into 293T cells with T7-expressing plasmid. The T7-driven recombinant SeV 18+ A␤1-43/TS F-mIL10 and SeV 18+ LacZ/TS F RNA genomes were encapsulated by NP, P, and L proteins, which were derived from their respective co-transfected plasmids. The recovered SeV vectors were propagated using F protein-expressing packaging cell line [23] . The virus titers were determined using infectivity and were expressed in cell infectious units (CIU). The SeV vectors were stored at −80 • C until use.
Vaccination with rSeV-Aˇ or rSeV-LacZ
rSeV was diluted with PBS to give 5 × 10 6 CIU/head in a final volume of 0.02 ml, and was administered once nasally or intramuscularly (left quadriceps) to 12-month-old Tg2576 mice for analysis of cognitive functions and body weight, or to 24-month-old Tg2576 mice for evaluation of amyloid burdens and A␤ contents in the brain. Control Tg2576 mice received rSeV-LacZ and were analyzed in the same way.
Pathological study
Tg2576 mice received the vaccine nasally or intramuscularly at the age of 24 months and were sacrificed 8 weeks after by CO 2 asphyxiation. Their brains were removed and cut in half sagittally.
Serum antibodies against Aˇ42
Anti-human A␤ antibody titers in the serum of nasally or intramuscularly vaccinated mice with rSeV-A␤ or rSeV-LacZ (n = 4 each) were quantified by a sandwich ELISA. Microtiter ELISA plates were coated overnight at 4 • C with 2 g/ml of synthetic human A␤1-42 in 0.1 M NaHCO 3 , pH 8.3, washed twice with washing buffer, blocked with 1% BSA and 2% normal goat serum in PBS for 2 h at room temperature (RT), washed twice and incubated with mouse serum samples diluted 1:500 in blocking buffer for 2 h at RT while shaking, washed × 4 and incubated horseradish peroxidaseconjugated goat-anti-mouse IgG for 2 h at RT, washed × 4 and analyzed colorimetrically after incubation with the chromogen substrate 3,3 ,5,5 -tetramethylbenzidine (Kirkegaard & Perry Laboratories, Gaithersburg) at RT.
Aˇ measurements in brain tissue by ELISA
Using highly specific antibodies and a sensitive sandwich ELISA, we quantified insoluble A␤40 and A␤42 in brain homogenates extracted with TBS, 2% SDS and 70% formic acid according to the method described [28] . The frozen brain tissue obtained from rSeV-A␤-treated and rSeV-LacZ-treated Tg2576 mice (n = 4 each) was homogenized in 1 ml of TBS/complete protease inhibitor and 20 g/ml pepstatin A (Roche, Indianapolis), then centrifuged at 100,000 × g for 1 h at 4 • C. The TBS supernatants were stored at −80 • C and the pellets were homogenized in 1 ml of 2% SDS/TBS with protease inhibitor (Roche), then centrifuged at 100,000 × g for 1 h at 25 • C following 15 min incubation at 37 • C. The pellet was washed once, then extracted further with 1 ml of 70% formic acid, and centrifuged at 100,000 × g for 1 h. The 70% formic acid extracts were neutralized with 1 M Tris-HCl, pH 8.0 at dilution of 1:20. For quantification of A␤ in the insoluble fractions, we used ␤-amyloid ELISA kit (Wako, Japan). The supernatant was diluted with standard dilution buffer at 1:2000 for A␤40 or 1:400 for A␤42 and measured according to the manufacturer's instructions. The obtained values were corrected with the wet weight of each brain hemisphere samples and expressed as pmol/g brain.
Western blot analysis for detection of Aˇ oligomers in soluble fraction
For analysis of A␤ oligomers in the SDS soluble fractions, 5 l of the supernatant referring to the sample preparation in ELISA was electrophoresed on 15/25% gradient SDS-PAGE gel (Daiichi, Japan) and transferred onto 0.2 m nitrocellulose membrane at 200 mA for 1 h. Filters were blocked with 5% non-fat milk in a 20 mM Tris-HCl, pH 7.4 containing 150 mM NaCl and 0.05% Tween 20 (TBS-T). After washing the membranes in TBS-T, monoclonal anti-A␤ antibody 6E10 (Senetek, Napa, CA) was used to probe the blots. Bound antibody was visualized using horseradish peroxidaseconjugated anti-mouse IgG (at 1:10,000) and ECL + detection (Amersham Pharmacia Biotech, Arlington Heights, IL).
Immunohistochemistry
Cryosections were fixed for 15 min with 70% formic acid for A␤ staining or 4% paraformaldehyde in 0.1 M phosphate buffer and rinsed with PBS-Triton before incubation in 0.3% H 2 O 2 in methanol for 30 min. Sections were incubated at RT for 2 h with antibody as indicated below. Sections were washed with PBS-Triton before incubation with secondary goat anti-mouse or anti-rabbit antibodies for 2 h. After PBS-Triton washes, sections were stained by the avidin-biotin HRP/DAB method. For immunofluorescent labeling, the fluorochromated immunoreagents were applied at a concentration of 20 g/ml PBS containing 1% BSA and 2% normal goat serum. A␤ plaque-containing sections were stained with polyclonal rabbit anti-A␤ antibody (Senetek, Napa, CA). The following primary antibodies were used at 1:50: CD3e, CD4, CD86, CD19 and CD11b (BD Biosciences Pharmingen, San Jose, CA), Cy3-tagged anti-mouse GFAP (Sigma, Saint Louis, MS; 1:400), and Iba-1 for microglia (kind gift from Dr. U. Imai, NCNP, Tokyo).
Quantitative analysis of A␤ burden was performed as described previously [21] in three different brain regions, the hippocampus, the frontal cortex, and the parietal association cortex of rSeV-LacZ-treated and rSeV-A␤-treated Tg2576 mice (n = 4 each). The A␤ burden was defined as the percentage of a brain region covered by A␤-immunoreactive deposits. Images were projected from an Olympus Vanox microscope onto a computer screen through a 3CCD Fujix digital camera and analyzed with an image analysis system (Mac Scope, Mitani Corporation).
Behavioral analysis
Experimental design
Cognitive dysfunctions are directly correlated with A␤ oligomers in Tg2576 mice, which start at around 6 months old and are stable until 14 months old [29] . Thus, we first evaluated cognitive functions in both non-tg (n = 18) and Tg2576 mice (n = 24) at the age of 12 months. After the behavioral test, mice were divided into two groups to be treated with rSeV-LacZ or rSeV-A␤. There is no difference between the two groups in behavioral scores at the age of 12 months. To evaluate the effect of vaccine treatment, each group (rSeV-LacZ-treated non-tg mice, n = 9; rSeV-A␤-treated non-tg mice, n = 9; rSeV-LacZ-treated Tg2576 mice, n = 10; rSeV-A␤-treated Tg2576 mice, n = 14) was subjected to behavioral tests at the age of 15 months. All tests were done according to the methods described previously [30] .
Novel-object recognition test
24 h after 10 min-training session following 3 day-habituation, each mouse was placed back into the same box in which one of the familiar objects used during training was replaced with a novel one. The animals were then allowed to explore freely for 10 min and the time spent exploring each object was recorded. The exploratory preference (%), a ratio of the amount of time spent exploring any one of the two objects (training session) or the novel object (retention session) over the total time spent exploring both objects was used to measure cognitive function.
Spontaneous alternation in a Y-maze test
Each mouse was placed at the center of the apparatus and allowed to move freely through the maze during an 8-min session, and the series of arm entries was recorded visually. Alternation was defined as successive entry into the three arms on overlapping triplet sets. The % alternation was calculated as the ratio of actual alternations to the possible alternations (defined as the number of arm entries minus two) multiplied by 100.
Morris water maze test
The Morris water maze test was conducted in a circular pool (1.2 m in diameter) with a hidden platform (7 cm in diameter) filled with water at a temperature of 22 ± 1 • C. The mice were given two trials (one block) for 10 consecutive days during which the platform was left in the same position. The time and distance taken to reach to the escape platform (escape latency and distance moved) was determined in each trial by using the Etho Vision system (Brainscience Co. Ltd., Osaka, Japan). Three hours after the last training trial, the platform was removed, and mice were allowed for 60 s to search the removed platform.
Cued and contextual fear conditioning tests
For measuring basal levels of freezing response (preconditioning phase), mice were individually placed in a neutral cage for 1 min, and then in the conditioning cage for 2 min. For conditioning, mice were placed in the cage, and an 80 dB tone was delivered for 15 s. During the last 5 s of the tone stimulus, a foot shock of 0.6 mA was delivered as an unconditioned stimulus through a shock generator (Brainscience idea Co. Ltd.). This procedure was repeated four times with 15-s intervals. Cued and contextual tests were carried out 1 day after fear conditioning. For the cued test, the freezing response was measured in the neutral cage for 1 min in the presence of a continuous-tone stimulus identical to the conditioned stimulus. For the contextual test, mice were placed in the conditioning cage, and the freezing response was measured for 2 min in the absence of the conditioned stimulus.
Statistic analysis
All results were expressed as the mean ± S.E.M. for each group. The difference among groups was analyzed with a one-way, twoway, or repeated ANOVA, followed by the Student-Newman-Keuls multiple range-test. The Student's t-test was used to compare two sets of data.
Results
Antibody response in the SeV-Aˇ-treated APP-tg mice
IgG antibodies to A␤ were detected in the serum of nasally treated Tg2576 mice with rSev-A␤ at 4 weeks and less amount at 8 weeks after vaccination ( Fig. 2a ). However, intramuscularly treated mice showed poor antibody response (not shown). The immune sera from nasally vaccinated mice stained the senile plaque amyloid in the tissue.
Reduction of Aˇ burden after nasal vaccine with rSeV-Aˇ in Tg2576 mice
Nasal vaccination with rSeV-A␤ resulted in marked reduction of A␤ burden in the frontal cortex, parietal association cortex and hippocampus compared to the control (Fig. 2b and c) . Thioflavin S-positive senile plaques were also significantly reduced in vaccinated mice. However, intramuscular injection of rSeV-A␤ had little effects on A␤ clearance ( Fig. 2d and e ). Quantitative analyses showed a marked reduction of A␤ deposition in nasally vaccinated mice compared to the control (Fig. 2f ), but intramuscular injection showed no difference in A␤ clearance (Fig. 2g) .
To investigate the expression of A␤43 in the olfactory bulb and brain stem through trafficking of rSeV via the olfactory or trigeminal nerves, we stained the brain tissue with anti-A␤43 antibody. Although Tg2576 mice expressed very little endogenous A␤43, we could not find any A␤43 depositions after the nasal administration of rSeV-A␤ (data not shown).
Aˇ contents in brain homogenates and Western blot analysis of Aˇ*56 oligomer
Soluble/insoluble A␤40 and A␤42 in brain homogenate fractions extracted with TBS or 2% SDS and 70% formic acid were quantified using the sandwich ELISA.
Nasal vaccination of rSeV-A␤ significantly reduced the contents of soluble and insoluble A␤40 and A␤42 compared to the control (A␤40 in TBS, p = 0.04; 2% SDS, p = 0.027; formic acid, p = 0.001. A␤42 in TBS, p = 0.008; 2% SDS, p = 0.01; formic acid, p = 0.045.) (Fig. 3A) , but again intramuscular injection of rSeV-A␤ was ineffective (A␤40 in TBS, p = 0.3; 2% SDS, p = 0.45; formic acid, p = 0.41. A␤42 in TBS, p = 0.15; 2% SDS, p = 0.27; formic acid, p = 0.48) (Fig. 3B ).
The trimeric, tetrameric, nonameric and dodecameric (A␤*56) A␤ oligomers in soluble fraction of Tg2576 mice were detected by using Western blotting. Nasal vaccination with rSeV-A␤ in Tg2576 mice resulted in a marked reduction in the contents of A␤*56 (dodecamer) but not in soluble sAPP␣ (Fig. 3C ).
Absence of brain inflammation and synaptic restoration after nasal vaccination with rSeV-AȞ
E staining of the brain sections of the vaccinated mice showed no lymphocyte infiltrations in the leptomeninges or brain parenchyma, and immunohistochemistry did not reveal any lymphocyte infiltrations, including CD3 + , CD4 + and CD8 + T cells and CD19 + B cells (data not shown).
In the hippocampus of the control APP-tg mice, there were many Iba-1 + and CD11b − microglia cells surrounding the senile plaques (Fig. 4a ), while nasally vaccinated mice with rSeV-A␤ showed the uniform distribution of Iba-1 + CD11b + microglia (Fig. 4b) . GFAP positive cells were less frequent in mice nasally vaccinated with rSeV-A␤.
Synaptophysin immunoreactivity was shrunken and disrupted in control mice with rSeV-LacZ. The nasally vaccinated mice with rSeV-A␤ showed the amelioration of abnormal change in synaptic densities and distribution patterns ( Fig. 4c and d) . Fig. 3 . Changes of brain A␤ levels after the nasal treatment with rSeV-A␤. Nasal rSeV-A␤ vaccine efficiently reduced the A␤40 and 42 levels in both soluble and insoluble fractions of the brain (A), but intramuscular administration was not efficient (B). rSeV-LacZ treated Tg2576 mice, n = 4; rSeV-A␤/mIL-10 treated Tg2576 mice, n = 4. Solid bars, controls; dotted bars, vaccine. A␤ oligomers particularly dodecamers (A␤*56) are apparently reduced in rSeV-A␤-treated mice nasally (n = 4) compared to rSeV-LacZ-treated mice (n = 4) (C).
Effect of rSeV-Aˇ on the body weight in Tg2576 mice
We examined the changes of body weight in Tg2576 mice treated with SeV-A␤ nasally at the age of 12 months. The body weight measured at the age of 15 months was 28.2 ± 1.4 g for rSeV-LacZ-vaccinated non-tg mice, 26.3 ± 1.1 g for rSeV-A␤vaccinated non-tg mice, 23.8 ± 0.9 g for rSeV-LacZ-vaccinated Tg2576 mice, and 22.6 ± 0.7 g for rSeV-A␤-vaccinated Tg2576 mice. Results with the two-way ANOVA were significantly different in genotype (F(1,38) = 17.08, p < 0.01) but not vaccination (F(1,38) = 2.24, p = 0.14) nor interaction of genotype with vaccination (F(1,38) = 0.10, p = 0.74).
Effect of nasal vaccination with rSeV-Aˇ on the impaired learning and memory
Object recognition in a novel-object recognition test
During the training session, there were no significant differences in exploratory preference between the two objects and total exploratory time among the groups (data not shown), suggesting that all groups of mice have the same levels of motivation, curiosity, and interest in exploring novel objects. For the retention session at age 12 months, the level of exploratory preference for the novel object in Tg2576 mice was significantly decreased compared to that in non-tg mice (supplemental Fig. 1) .
At age 15 months, the rSeV-LacZ-vaccinated Tg2576 mice also showed a significant reduction in the exploratory preference for the novel object compared with rSeV-LacZ-vaccinated non-tg mice, however rSeV-A␤ vaccination improved the impairment of recognition memory in Tg2576 mice significantly (supplemental Fig. 1 ).
Spontaneous alternation in a Y-maze test
There was no significant difference in the number of arm entries among the groups (data not shown), suggesting that all mice have the same levels of motivation, curiosity, and motor function. At age 12 months, Tg2576 mice showed significantly reduced spontaneous alternation behavior in a Y-maze test compared with non-tg mice (Fig. 5a) . At age 15 months, the rSeV-LacZ-vaccinated Tg2576 Fig. 4 . Immunohistochemical staining of microglia and synapses. There are many Iba-1 + microglia surrounding senile plaques in the brain of rSeV-LacZ-treated Tg2576 mice (a), while uniform distribution of Ibal + microglia was observed in mice treated with rSev-A␤ (b). Synaptophysin staining shows disruption of synapses in rSeV-LacZ-treated control mice (c), whereas amelioration is obvious in mice treated with rSev-A␤ (d). Scale bar: 100 m. mice also showed a significant reduction in spontaneous alternation behavior compared with rSeV-LacZ-vaccinated non-tg mice, however rSeV-A␤ vaccination improved alternation behavior in Tg2576 mice significantly (Fig. 5b ).
Associative learning in the cued and contextual fear conditioning tests
In the preconditioning phase, the mice hardly showed any freezing response. There were no differences in basal levels of freezing response between the groups (data not shown). In the contextual learning test, the rSeV-LacZ-and rSeV-A␤-vaccinated non-tg mice showed a marked contextual freezing response 24 h after fear conditioning. There was no difference in freezing response between the two groups of non-tg mice. However, the rSeV-LacZ-vaccinated Tg2576 mice exhibited significantly less freezing response in the contextual tests, indicating an impairment of associative learning, while the rSeV-A␤-vaccinated Tg2576 mice were indistinguishable from the rSeV-LacZ-vaccinated non-tg mice (Fig. 5c ).
In the cued learning test, there was no difference in the cued freezing response 24 h after fear conditioning among the groups. No alterations of nociceptive response were found in any of the mutant mice: there was no difference in the minimal current required to elicit flinching or jumping among the mice (Fig. 5d ).
Reference memory in the Morris water maze test
At the age 12 months, Tg2576 mice took significantly longer time and distance to reach the platform than non-tg mice, indicating an impairment of reference memory (Fig. 6A and B) . When the transfer test was carried out following the tenth training trial, Tg2576 mice showed a significant decrease in the time spent in the trained quadrant compared to non-tg mice (Fig. 6C) . At age 15 months, rSeV-A␤ vaccination improved all these parameters in Tg2576 mice significantly ( Fig. 6D-F) . The decreased ability of the rSeV-LacZ-vaccinated Tg2576 mice did not reflect a loss of swimming ability and motivation because swimming speed and distance in the transfer test were similar to those in other mice (data not shown).
Discussion
There are numerous approaches in active immunization therapies for AD [31] . An interesting approach to avoid autoimmune encephalitis is to avoid use of autoantigen A␤. Nasal administration of glatiramer acetate (GA) and adjuvant [32] or subcutaneous administration of GA alone [33] is reported safe and effective in Alzheimer model mice. GA is a synthetic random polymer composed of alanine, lysine, tyrosine and glutamic acid, which is now used for treatment of multiple sclerosis (MS). It has been speculated that GA activates regulatory T cells against myelin antigen-reactive auto-aggressive T cells, which in turn activates microglia, resulting in increased phagocytosis of amyloid. However, such non-specific clearance may not last for long. Further, GA must be injected everyday in MS.
Our nasal vaccine seems to be safe, easy, non-invasive and long lasting. Long term expression of recombinant protein in the mucosal epithelial cells and antigen presentation to the mucosal immune system have many advantages such as less frequent administrations and induction of continuous specific antibody production. In addition, majority of administered DNA is spontaneously eliminated in accordance with epithelial cell renewal.
SeV belonging to the Genus Respirovirus, infects and multiplies its genome copy in most mammalian cells, and expresses high levels of the transgene. Its replication is independent of nuclear functions and does not have a DNA phase during its life cycle, so it does not need to be concerned about the transformation of cells by integration of vector materials into the host chromosomes. These properties are very promising devices for gene therapy of new age (Cytoplasmic Gene Therapy) because of its genotoxicity-free nature. Further, it is non-pathogenic for humans. Since Sendai virus is a murine parainfluenza virus (PIV) with certain homologies to human PIV, it was tested as xenotropic vaccine in African Green monkeys and humans without any significant adverse reactions [34, 35] . Recombinant SeV vector carrying human PIV was also tested in rats [36, 37] . Further, recombinant SeV vaccine for human immunodeficiency virus (HIV) infection is going to be tested in humans (http://www.dnavec.co.jp/en/index.html). Thus, safety of Sendai virus vector is gradually established.
We inserted mouse IL-10 cDNA to construct rSeV-A␤ with the aim of helping antibodies productions and suppressing Th1 type T cell activations. Nasal administration of rSeV-A␤ without IL-10 had less effect to remove A␤ depositions (data not shown).
Recently, soluble A␤ oligomers, but not fibrils nor monomers, have been considered responsible for cognitive dysfunction prior to the formation of A␤ plaques [22] , and A␤*56, a 56-kDa soluble A␤ dodecamer was found responsible in Tg2576 mice [29] . Our nasal vaccine efficiently reduced not only senile plaque amyloid but also the contents of A␤*56 oligomer without changing sAPP␣ and improved cognitive dysfunction in water maze, Y-maze and contextual fear test which could evaluate hippocampus-related cognition. Thus, our vaccine, if applicable, can be given at the stage of mild cognitive impairment or earlier.
A␤ is released from presynaptic sites and deposited in extracellular plaques [38] , and APP and synaptophysin are co-localized at the growth cones of developing neurons in culture [39] . These reports have indicated that A␤ deposition plays an important role in degeneration of presynaptic structures. In addition, it is reported that A␤ oligomers directly disrupt synaptic structures [40] . In our study, synaptophysin staining showed amelioration of presynaptic degeneration following our nasal vaccine at 24 months old, suggesting prevention of synaptic degeneration or repair of synaptic structures after removal of A␤ deposits including A␤ oligomers. Results with the two-way ANOVA were: genotype; F(1,38) = 6.56, p < 0.05, vaccination; F(1,38) = 0.48, p = 0.49, interaction of genotype with vaccination; F(1,38) = 1.37, p = 0.25, *p < 0.05 vs rSeV-LacZ-vaccinated, non-transgenic mice. Our next plan is to see whether Tg2576 mice show improvement of cognitive functions by eliminating senile plaque amyloid even at 24 months old.
Conclusion
In conclusion, a new vaccine using Sendai virus vector with A␤ and IL-10 cDNA was developed. A nasal administration of this vaccine reduced amyloid burden including A␤ oligomers significantly in AD mice and improved cognitive functions without causing side effects such as brain inflammation. This vaccine can be used to treat and prevent Alzheimer disease.
